Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Graft vs Host Disease 1

Interventions

Specimen Handling 625pembrolizumab 606Magnetic Resonance Spectroscopy 550Carboplatin 448Cisplatin 396Cyclophosphamide 394Biopsy 371Paclitaxel 323Nivolumab 322Gemcitabine 317Radiotherapy 283Bevacizumab 242Dexamethasone 222fludarabine 213Docetaxel 198durvalumab 194Oxaliplatin 187venetoclax 186atezolizumab 179Fluorouracil 176Rituximab 175Pemetrexed 172Capecitabine 167Radiation 164Doxorubicin 164Radiosurgery 159Ipilimumab 145Etoposide 142Leucovorin 140Lenalidomide 138

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Emapalumab × 90 days × Clear all
NCT06996119 2026-05-11

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

City of Hope Medical Center

Phase 1 Recruiting
15 enrolled
MyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07567014 2026-05-06

Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS

NYU Langone Health

Phase 2 Not yet recruiting
60 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡